In the 28-week, phase three randomized control trial (RCT) DURATION-8, dual therapy with an SGLT2 inhibitor (dapagliflozin) and a GLP-1RA (once-weekly exenatide) was shown to reduce HbA1c by 0.4% more than either agent alone, in patients with a starting HbA1c of between 8-12% 50 , illustrating that the glycemic response to dual therapy is less than additive 50
But the risks of taking the wrong substance, dose or combination of products are real
Tolerability and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Inflammatory Bowel Disease
Diabetes, 38, 11651174 Crosignani, P.G., Colombo, M., Vegetti, W
When androgen activity increases, certain body areas may produce darker or coarser hair
Il rischio di tale pratica per elevatissimo: uno studio pubblicato su JAMA Network Open ha dimostrato come questi prodotti "alternativi" spesso non contengano le dosi esatte di farmaco e, in alcuni casi, risultino anche contaminati mettendo in pericolo chi li assume